Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in... Article history: Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparti- Received 4 November 2011 cles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The Received in revised form mean particle size and mean zeta potential of CUR–DOX–PBCA-NPs were 133 ± 5.34 nm in diam- 27 December 2011 eter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin Accepted 9 January 2012 were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the Available online 17 January 2012 formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5- diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded Keywords: PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs Curcumin (DOX–PBCA-NPs + CUR–PBCA-NPs), which was slightly higher than that of the free drug combination Doxorubicin (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR–PBCA-NPs or Poly(butyl cyanoacrylate) nanoparticles Multidrug resistance CUR + DOX–PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Pharmaceutics Elsevier

Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles

Loading next page...
 
/lp/elsevier/reversion-of-multidrug-resistance-by-co-encapsulation-of-doxorubicin-q0G1ZeKmlC
Publisher
Elsevier
Copyright
Copyright © 2012 Elsevier B.V.
ISSN
0378-5173
D.O.I.
10.1016/j.ijpharm.2012.01.020
Publisher site
See Article on Publisher Site

Abstract

Article history: Co-encapsulated doxorubicin (DOX) and curcumin (CUR) in poly(butyl cyanoacrylate) nanoparti- Received 4 November 2011 cles (PBCA-NPs) were prepared with emulsion polymerization and interfacial polymerization. The Received in revised form mean particle size and mean zeta potential of CUR–DOX–PBCA-NPs were 133 ± 5.34 nm in diam- 27 December 2011 eter and +32.23 ± 4.56 mV, respectively. The entrapment efficiencies of doxorubicin and curcumin Accepted 9 January 2012 were 49.98 ± 3.32% and 94.52 ± 3.14%, respectively. Anticancer activities and reversal efficacy of the Available online 17 January 2012 formulations and various combination approaches were assessed using 3-[4,5-dimethylthiazol-2-yl] 2,5- diphenyltetrazolium bromide assay and western blotting. The results showed that the dual-agent loaded Keywords: PBCA-NPs system had the similar cytotoxicity to co-administration of two single-agent loaded PBCA-NPs Curcumin (DOX–PBCA-NPs + CUR–PBCA-NPs), which was slightly higher than that of the free drug combination Doxorubicin (DOX + CUR) and one free drug/another agent loaded PBCA-NPs combination (DOX + CUR–PBCA-NPs or Poly(butyl cyanoacrylate) nanoparticles Multidrug resistance CUR + DOX–PBCA-NPs). The simultaneous administration of doxorubicin and curcumin achieved the highest reversal efficacy and down-regulation of P-glycoprotein in MCF-7/ADR cell lines, an MCF-7 breast carcer cell line resistant to adriamycin. Multidrug resistance can be enhanced

Journal

International Journal of PharmaceuticsElsevier

Published: Apr 15, 2012

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial